Possible nirmatrelvir/ritonavir-induced bradycardia in a patient with asymptomatic COVID-19
COVID-19 emerged in 2019 and was declared a pandemic by the World Health Organization in March 2020. COVID-19 is highly transmissible and can lead to bilateral pneumonia with severe respiratory failure. COVID-19 has led to more than 6.5 million deaths worldwide. The significant morbidity and mortali...
Main Authors: | Elizabeth DeMarco, Matthew Turnipseed, Brian Clarke, Farhan Qadeer |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2023-04-01
|
Series: | SAGE Open Medical Case Reports |
Online Access: | https://doi.org/10.1177/2050313X231168304 |
Similar Items
-
Nirmatrelvir/Ritonavir for hemodialysis patients with COVID-19
by: Jiayue Lu, et al.
Published: (2023-05-01) -
Inpatient remdesivir versus nirmatrelvir-ritonavir in the progression of COVID-19
by: Dimple Patel, et al.
Published: (2023-06-01) -
Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark?
by: Yuan-Pin Hung, et al.
Published: (2022-02-01) -
Evaluation of nirmatrelvir + ritonavir therapy in patients with mild to moderate COVID-19
by: T.M. Levina, et al.
Published: (2024-03-01) -
Is the Combination Nirmatrelvir Plus Ritonavir Effective for Treating or Preventing COVID-19?
by: article Editorial
Published: (2022-12-01)